Aerovate Therapeutics (AVTE) Stock Forecast, Price Target & Predictions
AVTE Stock Forecast
Aerovate Therapeutics stock forecast is as follows: an average price target of $13.00 (represents a 377.94% upside from AVTE’s last price of $2.72) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
AVTE Price Target
AVTE Analyst Ratings
Aerovate Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 17, 2024 | Liisa Bayko | Evercore ISI | $2.00 | $1.65 | 21.21% | -26.47% |
Jun 17, 2024 | Eun Yang | Jefferies | $2.00 | $1.65 | 21.21% | -26.47% |
Apr 01, 2024 | Tiago Fauth | Wells Fargo | $35.00 | $29.57 | 18.36% | 1186.76% |
Mar 25, 2024 | Eun Yang | Jefferies | $65.00 | $26.95 | 141.19% | 2289.71% |
Aerovate Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 4 |
Avg Price Target | - | - | $26.00 |
Last Closing Price | $2.72 | $2.72 | $2.72 |
Upside/Downside | -100.00% | -100.00% | 855.88% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jun 18, 2024 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
Jun 17, 2024 | Cowen & Co. | - | Hold | Downgrade |
Jun 17, 2024 | Guggenheim | - | Neutral | Downgrade |
Jun 17, 2024 | Jefferies | - | Hold | Downgrade |
Jun 17, 2024 | BTIG | Buy | Neutral | Downgrade |
Apr 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Dec 06, 2022 | BTIG | - | Buy | Upgrade |
Aerovate Therapeutics Financial Forecast
Aerovate Therapeutics Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
High Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
Low Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-17.67M | $-16.48M | $-15.70M | $-21.00M | $-3.59M | $-5.18M | $-7.05M | $-9.49M | $-11.43M | $-13.42M | $-23.65M |
High Forecast | $-17.67M | $-16.48M | $-15.70M | $-21.00M | $-3.59M | $-5.18M | $-7.05M | $-9.49M | $-11.43M | $-12.74M | $-23.65M |
Low Forecast | $-17.67M | $-16.48M | $-15.70M | $-21.00M | $-3.59M | $-5.18M | $-7.05M | $-9.49M | $-11.43M | $-14.10M | $-23.65M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.13 | $-0.18 | $-0.24 | $-0.33 | $-0.40 | $-0.47 | $-0.82 |
High Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.13 | $-0.18 | $-0.24 | $-0.33 | $-0.40 | $-0.44 | $-0.82 |
Low Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.13 | $-0.18 | $-0.24 | $-0.33 | $-0.40 | $-0.49 | $-0.82 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
ACRV | Acrivon Therapeutics | $7.85 | $22.00 | 180.25% | Buy |
RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
ADAG | Adagene | $3.05 | $5.00 | 63.93% | Buy |
AVTE Forecast FAQ
Is Aerovate Therapeutics a good buy?
No, according to 5 Wall Street analysts, Aerovate Therapeutics (AVTE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of AVTE's total ratings.
What is AVTE's price target?
Aerovate Therapeutics (AVTE) average price target is $13 with a range of $2 to $35, implying a 377.94% from its last price of $2.72. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aerovate Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AVTE stock, the company can go up by 377.94% (from the last price of $2.72 to the average price target of $13), up by 1186.76% based on the highest stock price target, and down by -26.47% based on the lowest stock price target.
Can Aerovate Therapeutics stock reach $4?
AVTE's average twelve months analyst stock price target of $13 supports the claim that Aerovate Therapeutics can reach $4 in the near future.
What are Aerovate Therapeutics's analysts' financial forecasts?
Aerovate Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-25.305M (high $-25.305M, low $-25.305M), average SG&A $0 (high $0, low $0), and average EPS is $-0.88 (high $-0.88, low $-0.88). AVTE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $20.37M (high $20.37M, low $20.37M), average EBITDA is $0 (high $0, low $0), average net income is $-70.864M (high $-70.864M, low $-70.864M), average SG&A $0 (high $0, low $0), and average EPS is $-2.464 (high $-2.464, low $-2.464).